Beta-1A
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2274 publications
Clinical, demographic, and pharmacological predictors of medication adherence to disease-modifying therapies in multiple sclerosis: a multidimensional analysis of merged survey and claims data.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: March 10, 2026
Immunotherapy-Mediated Modulation of the Gut Microbiota in Multiple Sclerosis: The Effects of High-Efficacy (Cladribine) and Moderate-Efficacy (Interferon Beta-1a) Treatments.
Journal: International journal of molecular sciences
Published: March 07, 2026
Identification of Drug Repurposing Opportunities of Immunomodulatory Drugs for Inflammatory Bowel Disease Through Inverse Pharmacovigilance Signal Detection in the FAERS Database.
Journal: Journal of clinical medicine
Published: February 01, 2026
LncRNA AFAP1-AS1 mediates therapy-dependent expression of CCL5, CXCL10 and MMP9 in multiple sclerosis.
Journal: Biochemistry and biophysics reports
Published: January 19, 2026
The comparative efficacy of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis: Updated meta-regression estimates by patient subgroup.
Journal: Multiple sclerosis and related disorders
Published: December 20, 2025
Updated systematic literature review and network meta-analysis of cladribine tablets versus currently approved disease-modifying treatments for active relapsing-remitting multiple sclerosis.
Journal: Multiple sclerosis and related disorders
Published: December 19, 2025
Appendicitis and multiple sclerosis disease-modifying therapies: a disproportionality analysis of the FDA adverse event reporting system.
Journal: Multiple sclerosis and related disorders
Published: December 12, 2025
Therapeutic Outcomes of Fingolimod and Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis: A Real-World Study from Jordan.
Journal: Medicina (Kaunas, Lithuania)
Published: December 11, 2025
Reduced peripheral serotonin levels in women with multiple sclerosis: associations with underweight status, treatment duration, and use of interferon beta 1a.
Journal: Frontiers in cellular neuroscience
Published: November 24, 2025
Efficacy and tolerability of metformin as an adjuvant therapy in patients with relapse-remitting multiple sclerosis receiving interferon Beta 1a: A randomized pilot trial.
Journal: Journal of neuroimmunology
Published: November 08, 2025
Multiple sclerosis-associated EBNA2 variants influence the response to peginterferon beta-1a therapy.
Journal: Journal of autoimmunity
Published: November 07, 2025
Evaluating use of disease-modifying therapies for multiple sclerosis using claims data.
Journal: Frontiers in health services
Published: September 29, 2025
Last Updated: 06/30/2026